Allogeneic ABCB5-positive Stem Cells for Treatment of Epidermolysis Bullosa

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1/PHASE2

Total Enrollment

16 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-02-16

Study Completion Date

2021-11-26

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this clinical trial is to investigate the efficacy (by monitoring overall improvement of EB symptoms) and safety (by monitoring adverse events) of three doses of allo-APZ2-EB administered intravenously to patients with recessive dystrophic epidermolysis bullosa (RDEB).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Allogeneic ABCB5-positive Dermal Mesenchymal Stromal Cells for Treatment of Epidermolysis Bullosa (Phase III)

NCT05838092

Epidermolysis Bullosa

ACTIVE_NOT_RECRUITING PHASE3

Biochemical Correction of Severe EB by Allo HSCT and "Off-the-shelf" MSCs

NCT01033552

Epidermolysis Bullosa

COMPLETED PHASE1/PHASE2

A Study of FCX-007 for Recessive Dystrophic Epidermolysis Bullosa

NCT04213261

Recessive Dystrophic Epidermolysis Bullosa

ACTIVE_NOT_RECRUITING PHASE3

Recessive Dystrophic Epidermolysis Bullosa Screening for Possible Gene Transfer

NCT00533572

Epidermolysis Bullosa Dystrophica

TERMINATED

Mesenchymal Stromal Cells in Adults With Recessive Dystrophic Epidermolysis Bullosa

NCT02323789

Recessive Dystrophic Epidermolysis Bullosa

UNKNOWN PHASE1/PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is an interventional, single arm, non-randomized, open label, phase I/IIa clinical trial to investigate the efficacy and safety of the IMP allo-APZ2-EB in patients with RDEB.

Patients will undergo treatment with the IMP (three repeated intravenous applications) and will be followed up for efficacy for 12 weeks. To assess long-term safety of allo-APZ2-EB one follow-up visit at Month 12 and one follow-up visit at Month 24 post IMP applications is included.

Determination of the EB linked symptoms and quality of life will be assessed by using the EBDASI score, the iscorEB, the change in pain and itch perception, and patient's quality of life in EB. The wound healing process will be documented by photography.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Recessive Dystrophic Epidermolysis Bullosa

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

allo-APZ2-EB

intravenous infusion, three doses of allo-APZ2-EB (2 x 10\^6 cells/kg)

Group Type EXPERIMENTAL

allo-APZ2-EB

Intervention Type BIOLOGICAL

intravenous infusion of allo-APZ2-EB

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

allo-APZ2-EB

intravenous infusion of allo-APZ2-EB

Intervention Type BIOLOGICAL

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

allogeneic ABCB5-positive mesenchymal stem cells

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1\. Male or female patients aged between 0 and ≤55 years;

Staggered design for patient enrollment:

1. at least 3 adult patients (safety assessment 2 weeks after last treatment of third patient),
2. at least 3 patients ≥12 to \<18 years (safety assessment 2 weeks after first treatment of third patient),
3. at least 3 patients ≥5 to \<12 years (safety assessment 2 weeks after first treatment of third patient), and
4. at least 3 patients ≥12 months to \<5 years;
5. patients 0 to \<12 months (only in the UK);

2\. Diagnosed with RDEB (combined diagnosis by genotype assessment \[mutation analysis\] and correlating phenotype assessment \[wound assessment\]), patients must have a negative immunofluorescence test result on salt-split skin against proteins of the basement membrane at Visit 1 (existing test results will be accepted);

3\. Patient is eligible to participate in this clinical trial based on general health condition at the investigator's discretion;

US only:

Patient is eligible to participate in this clinical trial based on general health condition assessed by specific lab values (Hematology: Absolute neutrophil count \>1000/mm3 and platelet count \>150,000/mcL; Coagulation: PT and PTT \<2x the upper limit of normal for age; Hepatic: AST and ALT \<2x the upper limit of normal for age; Renal: Creatinine \<2x the upper limit of normal for age; Pulmonary: Oxygen saturation \>92% on room air and without supplemental oxygen requirement);

4\. Patient/legal representative understands the nature of the procedure and are providing written informed consent prior to any clinical trial procedure;

5\. Women of childbearing potential must have a negative urine pregnancy test at Visit 1;

6\. Women of childbearing potential and their partner must be willing to use highly effective contraceptive methods during the course of the clinical trial.

Exclusion Criteria

1. Tumor diseases or history of tumor disease;
2. Known positive result for human immunodeficiency virus 1 and/or 2;
3. Any known allergies to components of the IMP;
4. Evidence of any other medical conditions (such as psychiatric illness or active infection) based on physical examination, or laboratory findings that may interfere with the planned treatment, affect the patient's compliance, or place the patient at high risk of complications related to the treatment; at investigators discretion;
5. History of prior thrombosis or patients at risk for thrombosis;
6. Clinically significant or unstable concurrent disease or other clinical contraindications (based upon investigator's judgment);
7. Patient/legal representative anticipated to be unwilling or unable to comply with the requirements of the protocol;
8. Pregnant or lactating women;
9. Current or previous (within 30 days of enrollment) treatment with another IMP, or participation and/or under follow-up in another clinical trial;
10. Previous participation in this clinical trial (except for screening failures due to an exclusion criterion);
11. Known abuse of alcohol, drugs, or medicinal products;
12. Employees of the sponsor, or employees or relatives of the investigator.

Minimum Eligible Age

0 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No